Convalescent transfusion for pandemic influenza: Preparing blood banks for a new plasma product?

Transfusion

Volumn 50, Issue 6, 2010, Pages 1384-1398

  Leider, Jonathon P ^a,b   Brunker, Patricia A R ^a,b   Ness, Paul M ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 13D4; MONOCLONAL ANTIBODY A66; MONOCLONAL ANTIBODY CH2D9; MONOCLONAL ANTIBODY CR6261; MONOCLONAL ANTIBODY F10; MONOCLONAL ANTIBODY H5 HK97; MONOCLONAL ANTIBODY H5 VN04; MONOCLONAL ANTIBODY VN04 2; MONOCLONAL ANTIBODY VN04 3; OSELTAMIVIR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; BLOOD BANK; BLOOD DONOR; CANCER IMMUNOTHERAPY; DRUG EFFICACY; FATIGUE; FEVER; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION SENSITIVITY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; NAUSEA; NONHUMAN; NOTE; PANDEMIC; PLASMA TRANSFUSION; RISK BENEFIT ANALYSIS; SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; BLOOD BANKS; BLOOD COMPONENT TRANSFUSION; DISEASE OUTBREAKS; HUMANS; INFLUENZA, HUMAN; PLASMA;

EID: 77953085882     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02590.x     Document Type: Note

References (91)

1. WHO. Influenza-like illness in the United States and Mexico.
2. WHO. Influenza A(H1N1) - update 47.
3. WHO. What is phase 6?
4. WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO July 1 2009.
5. Li F, Choi B, Sly T, Pak A. Finding the real case-fatality rate of H5N1 avian influenza. BMJ 2008 62 : 555.
6. Fraser C, Donnelly CA, Cauchemez S, Hanage WP, Van Kerkhove MD, Hollingsworth TD, Griffin J, Baggaley RF, Jenkins HE, Lyons EJ, Jombart T, Hinsley WR, Grassly NC, Balloux F, Ghani AC, Ferguson NM, Rambaut A, Pybus OG, Lopez-Gatell H, Alpuche-Aranda CM, Chapela IB, Zavala EP, Guevara DM, Checchi F, Garcia E, Hugonnet S, Roth C WHO Rapid Pandemic Assessment Collaboration. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009 324 : 1557.
7. Vawter DE, Garrett JE, Prehn AW, DeBruin DA, Tauer CA, Parilla E, Liaschenko J, Marshall MF, Gervais KG. For the good of us all: ethically rationing health resources in Minnesota in a severe influenza pandemic.
8. U.S. Department of Health and Human Services, U.S. Department of Homeland Security. Guidance on allocating and targeting pandemic influenza vaccine.
9. Powell T, Christ KC, Birkhead GS. Allocation of ventilators in a public health disaster. Disaster Med Public Health Prep 2008 2 : 20.
10. Meslin EM, Alyea JM, Helft PR. Pandemic flu preparedness: ethical issues and recommendations to the Indiana State Department of Health.
11. Upshur R, Faith K, Gibson J, Thompson AK, Tracy CS, Wilson K, Singer PA. Stand on guard for thee: ethical considerations in preparedness planning for pandemic influenza.
12. Kotalik J. Preparing for an influenza pandemic: ethical issues. Bioethics 2005 19 : 422 31.
13. Kass NE, Otto J, O'Brien D, Minson M. Ethics and severe pandemic influenza: maintaining essential functions through a fair and considered response. Biosecur Bioterror 2008 6 : 227 36.
14. DARPA. 7-day biodefense.
15. WHO. Pandemic influenza preparedness and response: a WHO guidance document.
16. Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000 13 : 602 14.
17. Rubbo SD, Suri J. Passive immunization against tetanus with human immune globulin. BMJ 1962 2 : 79.
18. Casadevall A, Dadachova E, Pirofski L. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004 2 : 695 703.
19. Hemming VG. Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases. Clin Vaccine Immunol 2001 8 : 859 63.
20. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006 354 : 462 71.
21. Abbas A, Lichtman A. Cellular and molecular immunology. 5th updated ed.
22. Osterholm MT. Preparing for the next pandemic. N Engl J Med 2005 352 : 1839 42.
23. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007 21 : 101 17.
24. Talecris Biotherapeutics, Inc. Rabies immune globulin (human) HyperRAB™ S/D prescribing information.
25. Kim JH, Jacob J. DNA vaccines against influenza viruses. Curr Top Microbiol Immunol 2009 333 : 197.
26. Hayden FG. Antiviral resistance in influenza viruses - implications for management and pandemic response. N Engl J Med 2006 354 : 785 8. Accessed 3/9/2009.
27. Hill AW, Guralnick RP, Wilson MJ, Habib F, Janies D. Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza. Infect Genet Evol 2009 9 : 169 78.
28. Bregenholt S, Jensen A, Lantto J, Hyldig S, Haurum JS. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr Pharm Des 2006 12 : 2007 15.
29. Kubota-Koketsu R, Mizuta H, Oshita M, Ideno S, Yunoki M, Kuhara M, Yamamoto N, Okuno Y, Ikuta K. Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors. Biochem Biophys Res Commun 2009 387 : 180 5.
30. Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression systems: an overview of the current upstream technologies. Curr Pharm Biotechnol 2008 9 : 447 67.
31. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007 25 : 1421 34.
32. Ekiert DC, Bhabha G, Elsliger M, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. Antibody recognition of a highly conserved influenza virus epitope. Science 2009 324 : 246 51.
33. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M, Horowitz M, Horowitz L, Palese P, Bhatt RR, Lerner RA. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A 2008 105 : 5986 91.
34. Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab′)2 in mice. Respir Res 2006 7 : 43.
35. Shahzad M, Naeem K, Mukhtar M, Khanum A. Passive immunization against highly pathogenic avian influenza virus (AIV) strain H7N3 with antiserum generated from viral polypeptides protect poultry birds from lethal viral infection. Virol J 2008 5 : 144.
36. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, de Jong MD, Lanzavecchia A, Subbarao K. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med 2007 4 : e178.
37. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009 16 : 265 73.
38. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, Yoshida H, Mikayama T, Kubo RT, Sarawar S, Cheroutre H, Kato S. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antivir Res 2008 80 : 168 77.
39. Hanson BJ, Boon A, Lim A, Webb A, Ooi EE, Webby RJ. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006 7 : 126.
40. Lim AP, Wong SK, Chan AH, Chan CE, Ooi EE, Hanson BJ. Epitope characterization of the protective monoclonal antibody VN04-2 shows broadly neutralizing activity against highly pathogenic H5N1. Virol J 2008 5 : 80.
41. Lim AP, Chan CE, Wong SK, Chan AH, Ooi EE, Hanson BJ. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a fab-phage display library. Virol J 2008 5 : 130.
42. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE Jr. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008 455 : 532 6.
43. Garulli B, Castrucci MR. Protective immunity to influenza: lessons from the virus for successful vaccine design. Expert Rev Vaccines 2009 8 : 689 93.
44. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM memory B cells. PLoS ONE 2008 3 : e3942.
45. Webster R, Laver W, Air G, Schild G. Molecular mechanisms of variation in influenza viruses. Nature 1982 296 : 115 21.
46. Knossow M, Skehel JJ. Variation and infectivity neutralization in influenza. Immunology 2006 119 : 1 7.
47. HUI DSC. Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection. Respirology 2008 13 : 10.
48. Purcell R, Lockey R. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol 2008 18 : 335 42.
49. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006 355 : 1018.
50. Presta LG. Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 2008 20 : 460 70.
51. Jefferis R. Antibody therapeutics. Expert Opin Pharmacother 2007 7 : 1401 13.
52. Gleich GJ, Leiferman KM. Anaphylaxis: implications of monoclonal antibody use in oncology. Oncology (Huntingt) 2009 23 Suppl 1 : 7 13.
53. Diamandis EP. Immunoassay interference: a relatively rare but still important problem. Clin Biochem 2004 37 : 331 2.
54. Cole LA, Khanlian SA. Easy fix for clinical laboratories for the false-positive defect with the Abbott AxSym total β-hCG test. Clin Biochem 2004 37 : 344 9.
55. Levinson SS, Miller JJ. Towards a better understanding of heterophile (and the like) antibody interference with modern immunoassays. Clin Chim Acta 2002 325 : 1 15.
56. Nieri P, Donadio E, Rossi S, Adinolfi B, Podesta A. Antibodies for therapeutic uses and the evolution of biotechniques. Curr Med Chem 2009 16 : 753 79.
57. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008 453 : 667 71.
58. Bartlett JG. ABX guide. [cited 16 Jan 2010]. Available from: http://www.hopkins-abxguide.org/
59. DARPA. Accelerated manufacturing of pharmaceuticals.
60. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979 2 : 1216 7.
61. Chen X, Smith G, Zhou B, Qiu C, Wu WL, Li Y, Lu P, Duan L, Liu S, Yuan J, Yang G, Wang H, Cheng J, Jiang H, Peiris JS, Chen H, Yuen KY, Zhong N, Guan Y. Avian influenza A (H5N1) infection in a patient in China, 2006. Influenza Other Respi Viruses 2007 1 : 207 13.
62. Yu H, Gao Z, Feng Z, Shu Y, Xiang N, Zhou L, Huai Y, Feng L, Peng Z, Li Z, Xu C, Li J, Hu C, Li Q, Xu X, Liu X, Liu Z, Xu L, Chen Y, Luo H, Wei L, Zhang X, Xin J, Guo J, Wang Q, Yuan Z, Zhou L, Zhang K, Zhang W, Yang J, Zhong X, Xia S, Li L, Cheng J, Ma E, He P, Lee SS, Wang Y, Uyeki TM, Yang W. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS ONE 2008 3 : e2985.
63. Wang H, Feng Z, Shu Y, Yu H, Zhou L, Zu R, Huai Y, Dong J, Bao C, Wen L, Wang H, Yang P, Zhao W, Dong L, Zhou M, Liao Q, Yang H, Wang M, Lu X, Shi Z, Wang W, Gu L, Zhu F, Li Q, Yin W, Yang W, Li D, Uyeki TM, Wang Y. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet 371 : 1427 34.
64. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007 357 : 1450.
65. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006 145 : 599.
66. Enria DA, Briggiler AM, Sánchez Z. Treatment of argentine hemorrhagic fever. Antivir Res 2008 78 : 132 9.
67. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005 24 : 44 6.
68. Yeh KM, Chiueh TS, Siu LK, Lin JC, Chan PK, Peng MY, Wan HL, Chen JH, Hu BS, Perng CL, Lu JJ, Chang FY. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother 2005 56 : 919 22.
69. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004 126 : 11.
70. Domen RE, Hoeltge GA. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003 127 : 316 20.
71. Gilstad CW. Anaphylactic transfusion reactions. Curr Opin Hematol 2003 10 : 419.
72. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009 113 : 3406.
73. Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, O'Byrne MM, Evenson LK, Malinchoc M, DeGoey SR, Afessa B, Hubmayr RD, Moore SB. Transfusion related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007 176 : 886 91.
74. Benson AB, Moss M, Silliman CC. Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill. Br J Haematol 2009 147 : 431 43.
75. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007 21 : 327 48.
76. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 2003 13 : 387 98.
77. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989 40 : 444 51.
78. Tamura M, Webster R, Ennis F. Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 1991 182 : 211 9.
79. Gotoff R, Tamura M, Janus J, Thompson J, Wright P, Ennis FA. Primary influenza A virus infection induces cross-reactive antibodies that enhance uptake of virus into Fc receptor-bearing cells. J Infect Dis 1994 200 3.
80. Wells M, Albrecht P, Daniel S, Ennis F. Host defense mechanisms against influenza virus: interaction of influenza virus with murine macrophages in vitro. Infect Immun 1978 22 : 758 62.
81. Kuiken T, Taubenberger JK. Pathology of human influenza revisited. Vaccine 2008 26 : 59 66.
82. Likos AM, Kelvin DJ, Cameron CM, Rowe T, Kuehnert MJ, Norris PJ. Influenza viremia and the potential for blood-borne transmission. Transfusion 2007 47 : 1080 8.
83. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006 12 : 1203 7.
84. Korneyeva M, Rosenthal S. Virus removal by nanofiltration. Methods Mol Biol 2005 308 : 221 31.
85. Sandbulte MR, Jimenez GS, Boon A, Smith LR, Treanor JJ, Webby RJ. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007 4 : e59.
86. Chen Y, Qin K, Wu WL, Li G, Zhang J, Du H, Ng MH, Shih JW, Peiris JS, Guan Y, Chen H, Xia N. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes. J Infect Dis 2008 199 : 49 58.
87. Sun L, Lu X, Li C, Wang M, Liu Q, Li Z, Hu X, Li J, Liu F, Li Q, Belser JA, Hancock K, Shu Y, Katz JM, Liang M, Li D. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS ONE 2009 4 : e5476.
88. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog 2009 5 : e1000350.
89. Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, Qiang J, Meng T, Goutama M, Kwang J. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS ONE 2009 4 : e5672.
90. Prabhu N, Prabakaran M, Hongliang Q, He F, Ho HT, Qiang J, Goutama M, Lim AP, Hanson BJ, Kwang J. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza. Antivir Ther 2009 14 : 911 21.
91. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma. Hong Kong Med J 2006 12 : 489.